MarketCap
Facebook
X
Telegram
Tenax Therapeutics Total Non Current Liabilities | TENX
Annual Total Non Current Liabilities Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 64.2 K | 184 K | - | 60.4 K | - | - | - | 7.96 M | 7.97 M | 3.05 M | 1.36 M | 4.46 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.97 M | 60.4 K | 3.14 M |
Quarterly Total Non Current Liabilities Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | 64.2 K | 95.3 K | 126 K | 155 K | 184 K | 212 K | 239 K | 31.1 K | 124 K | 124 K | 124 K | 124 K | 60.4 K | 60.4 K | 60.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 239 K | 31.1 K | 119 K |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
59.2 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
57.5 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
37.2 M | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
58.7 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
20.4 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
953 K | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
1.45 M | - | - | $ 24.9 M | USA |
 |
Завод ДИОД
DIOD
|
89.5 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
13.2 M | - | - | - | Russia |
 |
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
2.39 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
127 K | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
132 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
4.72 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
95.3 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
2.22 M | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
25.2 M | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
Cellectis S.A.
CLLS
|
103 M | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
326 M | $ 12.03 | 1.78 % | $ 3.59 B | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
686 M | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
635 M | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
2.03 M | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
10.3 M | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
7.6 M | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
563 M | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
8.1 M | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
10.5 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
1.05 M | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
315 M | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
84.6 M | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
83.9 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
898 M | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Catalyst Biosciences
CBIO
|
981 K | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
186 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
4.63 M | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
58.3 M | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
83.9 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
24.6 M | $ 10.12 | 0.4 % | $ 289 M | USA |
|
Foghorn Therapeutics
FHTX
|
97.7 M | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
25.4 B | $ 13.76 | 4.13 % | $ 11.5 B |  India |